Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Assets (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Non-Current Assets readings, the most recent being $273.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 2.35% to $273.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 3.66% decrease, with the full-year FY2025 number at $273.7 million, down 2.35% from a year prior.
  • Non-Current Assets hit $273.7 million in Q4 2025 for Amicus Therapeutics, roughly flat from $274.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $308.3 million in Q4 2021 to a low of $273.7 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $298.8 million (2022), compared with a mean of $294.3 million.
  • The widest YoY moves for Non-Current Assets: up 0.41% in 2021, down 7.04% in 2021.
  • Amicus Therapeutics' Non-Current Assets stood at $308.3 million in 2021, then dropped by 2.58% to $300.4 million in 2022, then dropped by 1.84% to $294.8 million in 2023, then fell by 4.93% to $280.3 million in 2024, then fell by 2.35% to $273.7 million in 2025.
  • The last three reported values for Non-Current Assets were $273.7 million (Q4 2025), $274.7 million (Q3 2025), and $277.3 million (Q2 2025) per Business Quant data.